16:02 EDT Neurocrine (NBIX) backs FY25 INGREZZA net product sales view $2.5B-$2.55B
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ New Study on MDD Treatment: What Investors Need to Know
- Neurocrine Biosciences Advances Pediatric CAH Treatment with New Study
- NBIX Upcoming Earnings Report: What to Expect?
- Strong Buy Rating for Neurocrine Due to Robust Pipeline and Strategic Growth Potential
- Neurocrine initiated with a Buy at Citi